Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Metabolomes of mitochondrial diseases and inclusion body myositis patients: treatment targets and biomarkers.

Buzkova J, Nikkanen J, Ahola S, Hakonen AH, Sevastianova K, Hovinen T, Yki-Järvinen H, Pietiläinen KH, Lönnqvist T, Velagapudi V, Carroll CJ, Suomalainen A.

EMBO Mol Med. 2018 Dec;10(12). pii: e9091. doi: 10.15252/emmm.201809091.

2.

NS5A resistance leading to failure of 24-week therapy with sofosbuvir/ledipasvir and ribavirin for the treatment of hepatitis C genotype 1a infection in a HIV-1 co-infected patient.

Sevastianova K, Dean J, Bannan C, Coghlan M, Farrell G, Murray C, De Gascun CF, Bergin C.

J Clin Virol. 2016 Sep;82:66-69. doi: 10.1016/j.jcv.2016.06.012. Epub 2016 Jun 23.

PMID:
27454231
3.

Novel hepatic microRNAs upregulated in human nonalcoholic fatty liver disease.

Soronen J, Yki-Järvinen H, Zhou Y, Sädevirta S, Sarin AP, Leivonen M, Sevastianova K, Perttilä J, Laurila PP, Sigruener A, Schmitz G, Olkkonen VM.

Physiol Rep. 2016 Jan;4(1). pii: e12661. doi: 10.14814/phy2.12661.

4.

Liver fat content and hepatic insulin sensitivity in overweight patients with type 1 diabetes.

Llauradó G, Sevastianova K, Sädevirta S, Hakkarainen A, Lundbom N, Orho-Melander M, Groop PH, Forsblom C, Yki-Järvinen H.

J Clin Endocrinol Metab. 2015 Feb;100(2):607-16. doi: 10.1210/jc.2014-3050. Epub 2014 Nov 18.

PMID:
25405502
5.

Adipocyte size is associated with NAFLD independent of obesity, fat distribution, and PNPLA3 genotype.

Petäjä EM, Sevastianova K, Hakkarainen A, Orho-Melander M, Lundbom N, Yki-Järvinen H.

Obesity (Silver Spring). 2013 Jun;21(6):1174-9. doi: 10.1002/oby.20114.

6.

Adipose tissue is inflamed in NAFLD due to obesity but not in NAFLD due to genetic variation in PNPLA3.

Lallukka S, Sevastianova K, Perttilä J, Hakkarainen A, Orho-Melander M, Lundbom N, Olkkonen VM, Yki-Järvinen H.

Diabetologia. 2013 Apr;56(4):886-92. doi: 10.1007/s00125-013-2829-9. Epub 2013 Jan 19.

PMID:
23334462
7.

Effect of short-term carbohydrate overfeeding and long-term weight loss on liver fat in overweight humans.

Sevastianova K, Santos A, Kotronen A, Hakkarainen A, Makkonen J, Silander K, Peltonen M, Romeo S, Lundbom J, Lundbom N, Olkkonen VM, Gylling H, Fielding BA, Rissanen A, Yki-Järvinen H.

Am J Clin Nutr. 2012 Oct;96(4):727-34. Epub 2012 Sep 5.

PMID:
22952180
8.

CB(1) blockade-induced weight loss over 48 weeks decreases liver fat in proportion to weight loss in humans.

Bergholm R, Sevastianova K, Santos A, Kotronen A, Urjansson M, Hakkarainen A, Lundbom J, Tiikkainen M, Rissanen A, Lundbom N, Yki-Järvinen H.

Int J Obes (Lond). 2013 May;37(5):699-703. doi: 10.1038/ijo.2012.116. Epub 2012 Jul 17.

PMID:
22828945
9.

Genetic variation in PNPLA3 but not APOC3 influences liver fat in non-alcoholic fatty liver disease.

Hyysalo J, Stojkovic I, Kotronen A, Hakkarainen A, Sevastianova K, Makkonen J, Lundbom N, Rissanen A, Krauss RM, Melander O, Orho-Melander M, Yki-Järvinen H.

J Gastroenterol Hepatol. 2012 May;27(5):951-6. doi: 10.1111/j.1440-1746.2011.07045.x.

PMID:
22141340
10.

FGF-21 as a biomarker for muscle-manifesting mitochondrial respiratory chain deficiencies: a diagnostic study.

Suomalainen A, Elo JM, Pietiläinen KH, Hakonen AH, Sevastianova K, Korpela M, Isohanni P, Marjavaara SK, Tyni T, Kiuru-Enari S, Pihko H, Darin N, Õunap K, Kluijtmans LA, Paetau A, Buzkova J, Bindoff LA, Annunen-Rasila J, Uusimaa J, Rissanen A, Yki-Järvinen H, Hirano M, Tulinius M, Smeitink J, Tyynismaa H.

Lancet Neurol. 2011 Sep;10(9):806-18. doi: 10.1016/S1474-4422(11)70155-7. Epub 2011 Aug 3.

PMID:
21820356
11.

Comparison of dorsocervical with abdominal subcutaneous adipose tissue in patients with and without antiretroviral therapy-associated lipodystrophy.

Sevastianova K, Sutinen J, Greco D, Sievers M, Salmenkivi K, Perttilä J, Olkkonen VM, Wågsäter D, Lidell ME, Enerbäck S, Eriksson P, Walker UA, Auvinen P, Ristola M, Yki-Järvinen H.

Diabetes. 2011 Jul;60(7):1894-900. doi: 10.2337/db11-0075. Epub 2011 May 20.

12.

Genetic variation in PNPLA3 (adiponutrin) confers sensitivity to weight loss-induced decrease in liver fat in humans.

Sevastianova K, Kotronen A, Gastaldelli A, Perttilä J, Hakkarainen A, Lundbom J, Suojanen L, Orho-Melander M, Lundbom N, Ferrannini E, Rissanen A, Olkkonen VM, Yki-Järvinen H.

Am J Clin Nutr. 2011 Jul;94(1):104-11. doi: 10.3945/ajcn.111.012369. Epub 2011 Apr 27.

PMID:
21525193
13.

Increased coagulation factor VIII, IX, XI and XII activities in non-alcoholic fatty liver disease.

Kotronen A, Joutsi-Korhonen L, Sevastianova K, Bergholm R, Hakkarainen A, Pietiläinen KH, Lundbom N, Rissanen A, Lassila R, Yki-Järvinen H.

Liver Int. 2011 Feb;31(2):176-83. doi: 10.1111/j.1478-3231.2010.02375.x. Epub 2010 Dec 7.

PMID:
21134109
14.

Cholesterol synthesis is increased and absorption decreased in non-alcoholic fatty liver disease independent of obesity.

Simonen P, Kotronen A, Hallikainen M, Sevastianova K, Makkonen J, Hakkarainen A, Lundbom N, Miettinen TA, Gylling H, Yki-Järvinen H.

J Hepatol. 2011 Jan;54(1):153-9. doi: 10.1016/j.jhep.2010.05.037. Epub 2010 Aug 22.

PMID:
20947198
15.

Nonalcoholic fatty liver disease: detection of elevated nicotinamide adenine dinucleotide phosphate with in vivo 3.0-T 31P MR spectroscopy with proton decoupling.

Sevastianova K, Hakkarainen A, Kotronen A, Cornér A, Arkkila P, Arola J, Westerbacka J, Bergholm R, Lundbom J, Lundbom N, Yki-Järvinen H.

Radiology. 2010 Aug;256(2):466-73. doi: 10.1148/radiol.10091351.

PMID:
20656836
16.

Comparison of the relative contributions of intra-abdominal and liver fat to components of the metabolic syndrome.

Kotronen A, Yki-Järvinen H, Sevastianova K, Bergholm R, Hakkarainen A, Pietiläinen KH, Juurinen L, Lundbom N, Sørensen TI.

Obesity (Silver Spring). 2011 Jan;19(1):23-8. doi: 10.1038/oby.2010.137. Epub 2010 Jun 10.

17.

Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors.

Kotronen A, Peltonen M, Hakkarainen A, Sevastianova K, Bergholm R, Johansson LM, Lundbom N, Rissanen A, Ridderstråle M, Groop L, Orho-Melander M, Yki-Järvinen H.

Gastroenterology. 2009 Sep;137(3):865-72. doi: 10.1053/j.gastro.2009.06.005. Epub 2009 Jun 12.

PMID:
19524579
18.

Gene expression and immunohistochemistry in adipose tissue of HIV type 1-infected patients with nucleoside analogue reverse-transcriptase inhibitor-associated lipoatrophy.

Sievers M, Walker UA, Sevastianova K, Setzer B, Wågsäter D, Eriksson P, Yki-Järvinen H, Sutinen J.

J Infect Dis. 2009 Jul 15;200(2):252-62. doi: 10.1086/599986.

PMID:
19519254
19.

Adipose tissue inflammation and liver fat in patients with highly active antiretroviral therapy-associated lipodystrophy.

Sevastianova K, Sutinen J, Kannisto K, Hamsten A, Ristola M, Yki-Järvinen H.

Am J Physiol Endocrinol Metab. 2008 Jul;295(1):E85-91. doi: 10.1152/ajpendo.90224.2008. Epub 2008 Apr 22.

20.

Uridine supplementation for the treatment of antiretroviral therapy-associated lipoatrophy: a randomized, double-blind, placebo-controlled trial.

Sutinen J, Walker UA, Sevastianova K, Klinker H, Häkkinen AM, Ristola M, Yki-Järvinen H.

Antivir Ther. 2007;12(1):97-105.

PMID:
17503753
21.

HIV epidemiology in the Northwestern Federal District of Russia: dominance of HIV type 1 subtype A.

Smolskaya T, Liitsola K, Zetterberg V, Golovanova E, Kevlova N, Konovalova N, Sevastianova K, Brummer-Korvenkontio H, Salminen M.

AIDS Res Hum Retroviruses. 2006 Nov;22(11):1074-80.

PMID:
17147492
22.

Arterial stiffness in HIV-infected patients receiving highly active antiretroviral therapy.

Sevastianova K, Sutinen J, Westerbacka J, Ristola M, Yki-Järvinen H.

Antivir Ther. 2005;10(8):925-35.

PMID:
16430198
23.

Two viral strains and a possible novel recombinant are responsible for the explosive injecting drug use-associated HIV type 1 epidemic in Estonia.

Zetterberg V, Ustina V, Liitsola K, Zilmer K, Kalikova N, Sevastianova K, Brummer-Korvenkontio H, Leinikki P, Salminen MO.

AIDS Res Hum Retroviruses. 2004 Nov;20(11):1148-56.

PMID:
15588336

Supplemental Content

Loading ...
Support Center